NasdaqGM - Delayed Quote USD

Ocular Therapeutix, Inc. (OCUL)

4.9800 +0.0400 (+0.81%)
At close: 4:00 PM EDT
4.9800 0.00 (0.00%)
After hours: 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
59,843.0000
58,443.0000
51,494.0000
43,522.0000
17,403.0000
--
Cost of Revenue
5,393.0000
5,281.0000
4,540.0000
4,406.0000
2,083.0000
--
Gross Profit
54,450.0000
53,162.0000
46,954.0000
39,116.0000
15,320.0000
--
Operating Expense
145,900.0000
135,544.0000
125,608.0000
117,153.0000
78,167.0000
--
Operating Income
-91,450.0000
-82,382.0000
-78,654.0000
-78,037.0000
-62,847.0000
--
Net Non Operating Interest Income Expense
-6,279.0000
-7,355.0000
-6,224.0000
-6,638.0000
-6,600.0000
--
Other Income Expense
-17,537.0000
9,001.0000
13,840.0000
78,122.0000
-86,189.0000
--
Pretax Income
-115,266.0000
-80,736.0000
-71,038.0000
-6,553.0000
-155,636.0000
--
Net Income Common Stockholders
-115,266.0000
-80,736.0000
-71,038.0000
-6,553.0000
-155,636.0000
--
Average Dilution Earnings
--
-6,233.0000
-9,245.0000
-73,712.0000
--
--
Diluted NI Available to Com Stockholders
-121,499.0000
-86,969.0000
-80,283.0000
-80,265.0000
-155,636.0000
--
Basic EPS
-1.11
--
-0.92
-0.09
-2.56
-1.91
Diluted EPS
-1.12
--
-0.97
-0.98
-2.56
-1.91
Basic Average Shares
93,486.2760
--
76,875.0350
76,392.8700
60,752.2250
45,273.2310
Diluted Average Shares
99,255.5080
--
82,644.2670
82,162.1020
60,752.2250
45,273.2310
Total Operating Income as Reported
-91,450.0000
-82,382.0000
-78,654.0000
-78,037.0000
-62,847.0000
--
Total Expenses
151,293.0000
140,825.0000
130,148.0000
121,559.0000
80,250.0000
--
Net Income from Continuing & Discontinued Operation
-115,266.0000
-80,736.0000
-71,038.0000
-6,553.0000
-155,636.0000
--
Normalized Income
-97,729.0000
-89,738.0000
-84,879.0000
-84,674.0000
-69,447.0000
--
Interest Income
7,342.0000
3,983.0000
798.0000
33.0000
168.0000
--
Interest Expense
13,621.0000
11,338.0000
7,022.0000
6,671.0000
6,768.0000
--
Net Interest Income
-6,279.0000
-7,355.0000
-6,224.0000
-6,638.0000
-6,600.0000
--
EBIT
-101,645.0000
-69,398.0000
-64,016.0000
118.0000
-148,868.0000
--
EBITDA
-98,225.0000
-66,415.0000
-61,907.0000
2,539.0000
-146,095.0000
--
Reconciled Cost of Revenue
5,393.0000
5,281.0000
4,540.0000
4,406.0000
2,083.0000
--
Reconciled Depreciation
3,420.0000
2,983.0000
2,109.0000
2,421.0000
2,773.0000
--
Net Income from Continuing Operation Net Minority Interest
-115,266.0000
-80,736.0000
-71,038.0000
-6,553.0000
-155,636.0000
--
Total Unusual Items Excluding Goodwill
-17,537.0000
9,002.0000
13,841.0000
78,121.0000
-86,189.0000
--
Total Unusual Items
-17,537.0000
9,002.0000
13,841.0000
78,121.0000
-86,189.0000
--
Normalized EBITDA
-80,688.0000
-75,417.0000
-75,748.0000
-75,582.0000
-59,906.0000
--
12/31/2019 - 7/25/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EYPT EyePoint Pharmaceuticals, Inc.
9.08
-0.22%
 
FDMT 4D Molecular Therapeutics, Inc.
22.57
-0.66%
 
VTYX Ventyx Biosciences, Inc.
3.4400
+5.52%
 
KPTI Karyopharm Therapeutics Inc.
0.9668
+0.69%
 
AUPH Aurinia Pharmaceuticals Inc.
5.40
+1.89%
 
ETNB 89bio, Inc.
8.47
+4.57%
 
MDGL Madrigal Pharmaceuticals, Inc.
254.88
+4.31%
 
CYTK Cytokinetics, Incorporated
54.16
+2.60%
 
AKRO Akero Therapeutics, Inc.
22.99
-0.13%
 
IPSC Century Therapeutics, Inc.
3.3500
+13.95%